Disturbed angiogenic activity of adipose-derived stromal cells obtained from patients with coronary artery disease and diabetes mellitus type 2

Dzhoyashvili, Nina; Efimenko, Anastasia; Кочегура, Т. Н.; Ni, Kalinina; Koptelova, Natalia V; Sukhareva, Olga Yur'evna; Shestakova, Marina Vladimirovna; Акчурин, Р. С.; Tkachuk, Vsevolod A.; Parfyonova, Y.

doi:10.1186/s12967-014-0337-4

Cited by 71 publications

(69 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, a large number of AdSCs are required for a sufficient therapeutic effect. Considering these clinical applications, harvesting large numbers of cells from patients who are elderly or who have underlying diseases such as diabetes is often difficult and decreased cell‐trophic effects have also been reported . For these reasons, the favorable outcomes of AdSC treatment alone may be limited.…”

Section: Discussionmentioning

confidence: 99%

Cardiac Regeneration by Statin-Polymer Nanoparticle-Loaded Adipose-Derived Stem Cell Therapy in Myocardial Infarction

Yokoyama

Tabata

et al. 2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

Clinical trials with autologous adipose‐derived stem cell (AdSC) therapy for ischemic heart diseases (IHDs) are ongoing. However, little is known about combinational therapeutic effect of AdSCs and statin poly(lactic‐co‐glycolic) acid (PLGA) nanoparticles on the ischemic myocardium. We investigated the hypothesis that statins, which have pleiotropic effects, augment the therapeutic potential of AdSCs and that AdSCs also act as drug delivery tools. Simvastatin‐conjugated nanoparticles (SimNPs) significantly promoted migration activity without changing proliferation activity and upregulated growth factor gene expression in vitro. A small number of intravenously administered SimNP‐loaded AdSCs (10,000 cells per mouse) improved cardiac function following myocardial infarction, inducing endogenous cardiac regeneration in the infarcted myocardium. The de novo regenerated myocardium was thought to be derived from epicardial cells, which were positive for Wilms' tumor protein 1 expression. These findings were attributed to the sustained, local simvastatin release from the recruited SimNP‐loaded AdSCs in the infarcted myocardium rather than to the direct contribution of recruited AdSCs to tissue regeneration. SimNP‐loaded AdSCs may lead to a novel somatic stem cell therapy for IHDs. Stem Cells Translational Medicine 2019;8:1055–1067

show abstract

Section: Discussionmentioning

confidence: 99%

Cardiac Regeneration by Statin-Polymer Nanoparticle-Loaded Adipose-Derived Stem Cell Therapy in Myocardial Infarction

Yokoyama

Tabata

et al. 2019

Stem Cells Translational Medicine

View full text Add to dashboard Cite

show abstract

“…The tissue of origin can influence the secretome of these cells (Kalinina et al, 2015). Furthermore, MSCs derived from diseased donors may show negative clinical outcomes when used for therapies (Dzhoyashvili et al, 2014). Donor age is an important factor affecting MSC efficacy.…”

Section: Contrasting Results In Clinical Trials: Not All Mscs Are Equalmentioning

confidence: 99%

Five Decades Later, Are Mesenchymal Stem Cells Still Relevant?

Gomez-Salazar

Gonzalez-Galofre

Casamitjana

et al. 2020

Front. Bioeng. Biotechnol.

121

View full text Add to dashboard Cite

Mesenchymal stem cells are culture-derived mesodermal progenitors isolatable from all vascularized tissues. In spite of multiple fundamental, pre-clinical and clinical studies, the native identity and role in tissue repair of MSCs have long remained elusive, with MSC selection in vitro from total cell suspensions essentially unchanged as a mere primary culture for half a century. Recent investigations have helped understand the tissue origin of these progenitor cells, and uncover alternative effects of MSCs on tissue healing via growth factor secretion and interaction with the immune system. In this review, we describe current trends in MSC biology and discuss how these may improve the use of these therapeutic cells in tissue engineering and regenerative medicine.

show abstract

“…From experience with MSCs derived from bone marrow or adipose tissue it is known that age and morbidities of the donor can impair the number, viability, proliferation capacity, maximum life span and functional properties such as differentiation potential and proangiogenic factor secretion [16][17][18][19][20][21][22][23][24].…”

Section: Discussionmentioning

confidence: 99%

Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: Off-the-shelf GMP-manufactured donor-independent ATMP

Ballikaya¹,

Sadeghi²,

Niebergall-Roth³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Human dermal mesenchymal stromal cells (MSCs) expressing the ATP-binding cassette (ABC) efflux transporter ABCB5 represent an easily accessible MSC population that, based on preclinical and first-in-human data, holds significant promise to treat a broad spectrum of conditions associated not only with skin-related but also systemic inflammatory and/or degenerative processes.Methods: We developed and validated Good Manufacturing Practice-compliant expansion and manufacturing process by which ABCB5+ MSCs derived from surgical discard skin tissues are processed to an advanced-therapy medicinal product (ATMP) for clinical use. Enrichment for ABCB5+ MSCs is achieved in a three-step process involving plastic adherence selection, expansion in a highly efficient MSC-selecting medium and immunomagnetic isolation of the ABCB5+ cells from the mixed culture.Results: Product Quality Review data covering 324 cell expansions, 728 ABCB5+ MSC isolations, 66 ABCB5+ MSC batches and 85 final drug products reveal high process robustness and reproducible, reliable quality of the manufactured cell therapy product.Conclusion: We have successfully established an expansion and manufacturing process that enables the generation of homogenous ABCB5+ MSC populations of proven biological activity manufactured as a standardized, donor-independent, highly pure and highly functional off-the-shelf available ATMP, which is currently tested in multiple clinical trials.

show abstract

Disturbed angiogenic activity of adipose-derived stromal cells obtained from patients with coronary artery disease and diabetes mellitus type 2

Cited by 71 publications

References 57 publications

Cardiac Regeneration by Statin-Polymer Nanoparticle-Loaded Adipose-Derived Stem Cell Therapy in Myocardial Infarction

Cardiac Regeneration by Statin-Polymer Nanoparticle-Loaded Adipose-Derived Stem Cell Therapy in Myocardial Infarction

Five Decades Later, Are Mesenchymal Stem Cells Still Relevant?

Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: Off-the-shelf GMP-manufactured donor-independent ATMP

Contact Info

Product

Resources

About